Vortioxetine for the Treatment of Hoarding Disorder
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The present study is a single-group open-label investigation of the potential efficacy of
Vortioxetine for treatment of 30 adult volunteers with Hoarding Disorder (HD) (flexible-dose
study, with a target dose range 5-25mg). The proposed study will be the first Vortioxetine
study in HD, and conducted at the Anxiety Treatment and Research Clinic (ATRC) Canada's
largest academic anxiety clinic, a regional referral center for individuals with HD. The
study requires a Letter of No Objection from Health Canada and the study will be approved by
Hamilton Integrated Research Ethics Board (HiREB).